EVENITY — Total revenues
Products & Services · Total revenuesAmgen EVENITY — Total revenues remained flat by 0.0% to $525.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 34.4%, from $390.75M to $525.00M. Over 2 years (FY 2023 to FY 2025), EVENITY — Total revenues shows an upward trend with a 34.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration, successful clinical adoption, or expanded patient access, while a decrease may signal increased competition, patent expiration, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross sales generated from the commercialization of a specific bone-building therapeuti...
Peer comparison
Comparable to product-specific revenue lines for specialty pharmaceuticals or biologics in the osteoporosis or chronic disease treatment markets.
amgn_segment_evenity_total_revenuesHistorical Data
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $1.16B | $1.56B | $2.10B |
| YoY Change | — | +34.7% | +34.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's evenity — total revenues?
- Amgen (AMGN) reported evenity — total revenues of $525.00M in Q4 2025.
- How has Amgen's evenity — total revenues changed year-over-year?
- Amgen's evenity — total revenues increased by 34.4% year-over-year, from $390.75M to $525.00M.
- What is the long-term trend for Amgen's evenity — total revenues?
- Over 2 years (2023 to 2025), Amgen's evenity — total revenues has grown at a 34.5% compound annual growth rate (CAGR), from $1.16B to $2.10B.
- What does evenity — total revenues mean?
- The total revenue generated from the sales of a specific bone-building therapeutic product.